Azedra (iobenguane I 131) / Lantheus - LARVOL DELTA

MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Active, not recruiting ➔ Completed

Trial completion • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor • CD34

The Usefulness of 131I-MIBG Myocardial Scintigraphy in a Case of Pure Autonomic Failure - First Report in the Literature. (PubMed, Ann Indian Acad Neurol) - No abstract available

Journal

131I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future. (PubMed, ESMO Open) - "The 131I-mIBG therapy plus melphalan is confirmed to be effective to reduce/control tumour burden. Further studies are needed to clarify the role and timing of this treatment and to integrate its role in the strategy of CAR-T cells."

Journal • CNS Tumor • Endocrine Disorders • Hematological Disorders • Mucositis • Neuroblastoma • Oncology • Pediatrics • Solid Tumor

Ex vivo-expanded and activated haploidentical natural killer cells infusion before autologous stem cell transplantation in high-risk neuroblastoma: a phase I/II pilot study. (PubMed, Cancer Immunol Immunother) - "After harvesting hematopoietic progenitor cells (HPCs), patients received an intravenous infusion of high-activity iodine-131 (131I)-meta-iodobenzylguanidine (131I-MIBG)...Our study shows that incorporating NK cell infusion before AHSCT as a component of the conditioning regimen for consolidative therapy in pediatric patients with high-risk NB can be safe and well tolerated. IRCT Registration Number: IRCT20140818018842N32."

Journal • P1/2 data • Preclinical • Bone Marrow Transplantation • CNS Tumor • Neuroblastoma • Oncology • Pediatrics • Solid Tumor • Transplantation • NCAM1

Tumor Dose-Response Relationship of [131I]MIBG Therapy in Patients with Neural Crest Tumors by Means of [124I]MIBG PET. (PubMed, J Nucl Med) - "A single 24-h uptake assessment showed predictive value with respect to receiving the target dose. This study demonstrated a clear correlation between tumor-absorbed dose and functional response in [131I]MIBG therapy and proposes a target dose for response at the tumor level."

Journal • Cardiovascular • CNS Tumor • Endocrine Cancer • Hypertension • Neuroblastoma • Oncology • Solid Tumor

Harmonization of practice of release of patients after radiopharmaceutical therapy. (PubMed, J Radiol Prot) - "The study was performed for the following radiopharmaceuticals: 177Lu-PSMA-617, 177Lu-DOTATATE, Na131I, 131I-mIBG, 153Sm-oxabifor. Based on results, it is recommended to follow the approach based on the radioactive decay of radionuclide and dose constrain to members of the public in contact with patient of 1 mSv per one radiopharmaceutical administration and keep patient in the nuclear medicine department after radiopharmaceutical administration for at least 4-6 hours. Patient release criteria defined according to that approach comply with patient release criteria operated in different countries and allow maintaining radiation safety of the public."

Harmonization • Journal

Late nephrotoxicity of peptide receptor radionuclide therapy (PRRT) and impact of selected factors – A single centre cohort study (ENETS 2025) - "AIM(S) To evaluate the nephrotoxicity treatment with 90Y-DOTATATE and tandem therapy 90Y-DOTATATE+177Lu-DOTATATE in patients with neuroendocrine tumours (NETs) including the impact of selected factors that can potentiate kidney damage, as: age, 131IMIBG therapy, chemotherapy, diabetes, arterial hypertension, number of CT scans. CONCLUSION PRRT is an effective therapy, but during the qualification process, it is important to take into account kidney function and after its completion, patients require lifelong monitoring of kidney function. It is necessary to seek factors that may worsen radioisotope-induced kidney damage."

Clinical • Cardiovascular • Diabetes • Diabetic Nephropathy • Endocrine Cancer • Metabolic Disorders • Nephrology • Neuroendocrine Tumor • Oncology • Pulmonary Arterial Hypertension • Renal Disease • Solid Tumor

Urinary Dopamine Levels Can Predict the Avidity of Post-Therapy [131I]MIBG Scintigraphy in Unresectable or Metastatic Pheochromocytomas and Paragangliomas: A Preliminary Clinical Study. (PubMed, Pharmaceuticals (Basel)) - " Age and urinary dopamine levels may predict non-avid lesions in unresectable/metastatic PPGLs, aiding treatment decisions for [131I]MIBG therapy. This article is a revised and expanded version of a paper entitled "Urine dopamine level and age can predict non-avid lesion on scintigraphy after I-131 MIBG treatment for unresectable/metastatic PPGL", which was presented at SNMMI 2024, Toronto, from 8 June to 11 June 2024."

Journal • CNS Tumor • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better. (PubMed, J Nucl Med) - "[123I]metaiodobenzylguanidine (MIBG) imaging and [131I]MIBG treatment, which target this physiologic pathway, have been in clinical practice for 40 y. Although therapy outcomes have been favorable, [131I]MIBG use has not yet been optimized...Barriers to progress discussed included the unpredictable radioisotope supply, production of novel radiopharmaceuticals, lack of data regarding which are the best combination therapies, and insufficient clinical facilities. The aim was to stimulate the development and assessment of more effective treatments."

Journal • CNS Tumor • Neuroblastoma • Oncology • Pediatrics • Solid Tumor • SSTR

Advances in multimodal imaging for adrenal gland disorders: integrating CT, MRI, and nuclear medicine. (PubMed, Jpn J Radiol) - "Systemic complications associated with CS, and the diagnosis and treatment of pheochromocytomas, paragangliomas (PPGLs), and neuroblastomas, will also be discussed focusing on 123I-metaiodobenzylguanidine (MIBG) imaging and 131I-MIBG therapy...Additionally, the broad differential diagnosis for adrenal masses-including malignancies like adrenal carcinoma, metastases, and malignant lymphoma, as well as benign conditions like myelolipoma and ganglioneuroma, and complications, such as adrenal hemorrhage, infarction, and infections-will be outlined. The goal of this review was to provide an overview of adrenal diseases that includes the most recent information for radiologists to stay updated on the latest imaging techniques and advancements that can ensure accurate diagnosis and effective management."

Journal • Review • Adrenal Cortex Carcinoma • CNS Tumor • Congenital Adrenal Hyperplasia • Cushing’s Disease • Endocrine Cancer • Endocrine Disorders • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Nephrology • Neuroblastoma • Oncology • Solid Tumor

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: May 2025 ➔ May 2026 | Trial primary completion date: May 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Endocrine Cancer • Neuroblastoma • Oncology • Solid Tumor • CD34

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (clinicaltrials.gov) - P1 | N=99 | Active, not recruiting | Sponsor: Children's Oncology Group | Trial completion date: Sep 2024 ➔ Sep 2025

Trial completion date • Bone Marrow Transplantation • CNS Tumor • Ganglioneuroblastoma • Neuroblastoma • Oncology • Solid Tumor • Transplantation • MYCN

131I-mIBG THERAPY IN RELAPSED/REFRACTORY NEUROBLASTOMA: A WEAPON FROM THE FUTURE PAST. (PubMed, Crit Rev Oncol Hematol) - "Neuroblastoma (NB) is the most common extracranial solid tumor in children, with variable outcomes ranging from spontaneous remission to high-risk cases often leading to relapse or refractory disease. Our systematic review, based on MEDLINE, EMBASE, and Cochrane CENTRAL databases up to December 2023, evaluates the effectiveness and toxicity of ¹³¹I-mIBG therapy in relapsed/refractory NB. It also discusses its potential role in conjunction with emerging therapies like CAR-T cells, haploidentical stem cell transplantation, and dinutuximab beta."

IO biomarker • Journal • Review • Bone Marrow Transplantation • CNS Tumor • Neuroblastoma • Oncology • Pediatrics • Solid Tumor • Transplantation

Subsequent Thyroid Carcinomas in Children and Adolescents Registered in the German MET Consortium (1997-2023). (PubMed, Thyroid) - "Two patients received 131I-metaiodobenzylguanidine treatment...Subsequent DTCs following chemotherapy only versus chemo- and radiotherapy DTCs were larger and diagnosed in younger patients after a shorter latency. More research is needed to identify risk factors and mechanisms potentially contributing to thyroid tumorigenesis post-chemotherapy."

Journal • Bone Marrow Transplantation • Endocrine Cancer • Hematological Malignancies • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Transplantation

Pineal Gland Activity in Advanced-Stage Pediatric Neuroblastoma Patients on 68Ga-DOTATATE PET/CT. (PubMed, Clin Nucl Med) - "Although surgical intervention serves as the primary treatment for early-stage disease, advanced-stage cases necessitate a variety of oncologic therapeutic approaches, including 131I-MIBG and peptide receptor radionuclide therapy. Herein we report incidental pineal gland activity, represented in 68Ga-DOTATATE PET/CT (SSTR-PET) in 3 pediatric patients diagnosed with stage 4 neuroblastoma, related to the physiological distribution of radiopharmaceuticals."

Journal • Metastases • CNS Tumor • Neuroblastoma • Oncology • Pediatrics • Solid Tumor • SSTR

Inbraced: Phase I Study of 131-I MIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children with Relapsed/refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=44 | Active, not recruiting | Sponsor: University Hospital Southampton NHS Foundation Trust | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2024 ➔ May 2025

Enrollment closed • Trial primary completion date • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor

MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Trial primary completion date: Jun 2023 ➔ Feb 2024

Trial primary completion date • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor • CD34

Norepinephrine Transporter-Targeted Cancer Theranostics-New Horizons. (PubMed, Clin Nucl Med) - "In the evolving landscape of precision oncology, this review delineates the role of radiopharmaceuticals targeting the norepinephrine transporter (NET), with a particular focus on the current clinical application of 123I-MIBG diagnostic imaging and 131I-MIBG therapeutics, in particular for pheochromocytoma, neuroblastoma, or paraganglioma. We will also highlight recently introduced 18F-labeled NET targeting imaging radiotracers, which would offer unparalleled resolution, enhanced tumor localization, and staging properties. Complementing these novel second-generation PET agents in a theranostic approach, astatine-211 meta-astatobenzylguanidine (211At-MABG) would leverage the advantages of alpha-particles to selectively target and eradicate NET-expressing tumor cells with minimal off-target effects."

Journal • CNS Tumor • Endocrine Cancer • Neuroblastoma • Oncology • Solid Tumor

Dosimetry-guided 131I-mIBG Therapy in a Hemodialysis-Dependent Paraganglioma Patient Celeste Winters, Burcak Yilmaz, Anna Mench, Catherine Meyer, Evan Dodson, Nadine Mallak, Erik MittraDepartment of Diagnostic Radiology, OHSU, Portland, OR. BACKGROUND A 63 year old male patient with paraganglioma, type 2 diabetes mellitus, hypertension, and end stage renal disease requiring hemodialysis (HD)... (NANETS 2024) - "CONCLUSIONS Dosimetry-guided treatment with 131I-mIBG in patients requiring hemodialysis is feasible. With appropriate activity reduction, the treatment can be effective with limited side effects."

Adverse events • Clinical • Cardiovascular • CNS Tumor • Diabetes • Diabetic Nephropathy • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Oncology • Pain • Renal Disease • Solid Tumor • Type 2 Diabetes Mellitus

Sourcing and Availability: Issues with Alpha Emitters and Post-Azedra Therapy Options (NANETS 2024) - No abstract available

Why do patients with pheochromocytomas/paragangliomas exhibit significantly inconsistent elevation of catecholamines and their metabolites? a large Chinese cohort study. (PubMed, Endocrine) - "Plasma MNs exhibited a superior sensitivity than 24-h-urinary CAs in the Chinese PPGL diagnosis. Patients with a small tumor, normal blood pressure and negative 131I-MIBG imaging were prone to express negative biochemical levels. Additionally, an obvious elevation of 24-h-urinary CAs than plasma MNs was correlated to paroxysmal hypertension and the Epinephrine type."

Journal • Cardiovascular • CNS Tumor • Endocrine Cancer • Hypertension • Oncology • Solid Tumor

1203 Combination Therapies from Mouse to Man (EANM 2024) - "Approved RLT agents like 177Lu-DOTATATE, 131I-metaiodobenzylguanidine and 177Lu-PSMA treat neuroendocrine tumors, neuroblastoma, and metastatic castration-resistant prostate cancer, respectively. Additionally, the (ongoing) clinical studies combining RLT with immunotherapies will be highlighted. At last, the session will provide an outlook towards possible new combination approaches."

Combination therapy • Preclinical • CNS Tumor • Endocrine Cancer • Genito-urinary Cancer • Neuroblastoma • Neuroendocrine Tumor • Oncology • Prostate Cancer • Solid Tumor

Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics (clinicaltrials.gov) - P=N/A | N=159 | Completed | Sponsor: Peking Union Medical College Hospital

New trial • CNS Tumor • Endocrine Cancer • Oncology • Solid Tumor

Locoregional control in high-risk neuroblastoma using highly-conformal image-guided radiotherapy, with reduced margins and a boost dose for residual lesions. (PubMed, Radiother Oncol) - "In HR-NBL, IGRT with reduced margins and a boost dose for residual lesions ≥ 1 cm3 demonstrated excellent locoregional control, comparable to modern literature."

Journal • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor • MYCN

Insights and Recommendations on the Study of HSA-131I-MIBG Treatment for Advanced Pheochromocytoma and Paraganglioma. (PubMed, Clin Nucl Med) - No abstract available

Journal • Metastases • CNS Tumor • Endocrine Cancer • Oncology • Solid Tumor